Digital therapeutics have potential but commercial success unproven
Software can be a medical device. Can it also be a drug?
Lynparza’s latest win sets up Astra-Glaxo battle
Success for Lynparza in first-line ovarian cancer, regardless of BRCA mutation status, could see Astrazeneca’s drug regain the upper hand against Glaxosmithkline’s…
Biopharma's biggest sellers – the oldies that just keep giving
Patent expiries and challenges have done little to halt the sales of some of the industry's biggest products.
Medtech
Digital therapeutics have potential but commercial success unproven
Software can be a medical device. Can it also be a drug?
Company Events
Reata gets another shot in Friedreich’s ataxia
Reata Pharmaceuticals will soon find out if its decision to persevere with omaveloxolone despite an earlier failure has paid off.
Medicines Company goes on the hunt for heartening Orion data
The Medicines Company needs to show decent efficacy and pristine safety with its long-lasting PCSK9 inclisiran to stand a chance of disrupting the market.
FDA adcom to pronounce on paclitaxel-coated devices
The recent disappointing sales of drug-coated devices for peripheral arterial disease look likely to become the norm.
Interviews
Digital therapeutics have potential but commercial success unproven
Software can be a medical device. Can it also be a drug?
Ablative Solutions has a fight on its hands in renal denervation
Alcohol kills – and in this case, that could be a good thing.
Vizai hopes Medtronic deal will boost sales of its tech – and vice versa
Medtronic decides that Solitaire is best played with a partner.